A5067438053- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Spectroscopy Techniques in Biomedical and Chemical Research
- Immunotherapy and Immune Responses
- Brain Tumor Detection and Classification
- CAR-T cell therapy research
- Advancements in Semiconductor Devices and Circuit Design
- Cancer, Hypoxia, and Metabolism
- Photoacoustic and Ultrasonic Imaging
- Brain Metastases and Treatment
- Frailty in Older Adults
- Molecular Biology Techniques and Applications
WinnMed
2024
Jacksonville College
2023-2024
Mayo Clinic in Florida
2023-2024
INTRODUCTION: Glioblastoma (GBM) is the most common and aggressive primary brain cancer, with a median overall survival of 14.6 months. The standard care (SOC) has remained unchanged for nearly two decades, comprising supramarginal resection followed by postoperative fractionated radiotherapy concomitant temozolomide. Despite significant resources invested to advance field, alternatives are limited, calling much-needed paradigm shift. While Stereotactic Radiosurgery (SRS) commonly utilized...
INTRODUCTION: Glioblastoma (GBM) recurrence is the rule rather than exception. GBM cells invading healthy brain and tumor microenvironment are believed to be responsible for recurrence. However, little known about molecular alterations in primary that drive this progression. Multi-omics studies have revealed specific tissue domains of could higher invasive profiles (pGBM) recurrent (rGBM) tumors. METHODS: Paraffin-embedded sample blocks from matched (n = 8) 10) were utilized. Spatial...
BACKGROUND AND OBJECTIVES: Despite standard of care with maximal safe resection and chemoradiation, glioblastoma (GBM) is the most common aggressive type primary brain cancer. Surgical provides a window opportunity to locally treat gliomas while patient recovering before initiating concomitant chemoradiation. The objective was assess safety establish maximum tolerated dose adipose-derived mesenchymal stem cells (AMSCs) for treatment recurrent GBM. Secondary objectives were toxicity profile...
Abstract Accurate response assessment in patients with high-grade gliomas (HGGs) is complicated by post-treatment radiographic changes that are equivocal for treatment effect versus progression. Plasma-based liquid biopsy assays circulating tumor DNA (ctDNA) have had limited sensitivity to date, due part the presence of blood-brain barrier limits diffusion tumor-derived analytes out central nervous system. To address this challenge, we developed a ctDNA plasma-based assay detect...
With the goal to overcome limited treatment options and poor prognosis of glioblastoma (GBM), we have developed a PD-L1-targeting CAR T cell therapy, MC9999. In vitro experiments with MC9999 cells derived from GBM patients exhibited potent, antigen-specific cytotoxicity against autologous tumor immunosuppressive within microenvironment (TME). an orthotopic model using patient-derived brain tumor-initiating cells, intracranial delivery eradicated established tumors improved survival....
INTRODUCTION: Despite advances in the understanding of brain cancer, surgery and extent resection (EOR) continue to be main predictors patient outcome. However, currently available public biorepositories do not include for individual patients raising important questions regarding confounding effects some molecular markers. Further, emerging data has supported novel biomarkers tumor’s lipidome optical attenuation properties which could serve as new therapeutic opportunities. METHODS: All...